Twist Bioscience (NASDAQ:TWST) Insider Dennis Cho Sells 1,099 Shares of Stock

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 1,099 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $46.58, for a total value of $51,191.42. Following the completion of the sale, the insider directly owned 143,581 shares of the company’s stock, valued at $6,688,002.98. The trade was a 0.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Dennis Cho also recently made the following trade(s):

• On Monday, December 22nd, Dennis Cho sold 324 shares of Twist Bioscience stock. The shares were sold at an average price of $34.56, for a total transaction of $11,197.44.

Twist Bioscience Price Performance

Shares of NASDAQ TWST traded down $1.02 on Thursday, hitting $47.10. The company’s stock had a trading volume of 2,162,437 shares, compared to its average volume of 1,485,586. The company has a market capitalization of $2.89 billion, a price-to-earnings ratio of -36.80 and a beta of 2.24. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $54.74. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.78 and a quick ratio of 3.33. The stock has a 50 day moving average of $36.23 and a 200-day moving average of $31.84.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.02). The business had revenue of $103.70 million for the quarter, compared to analyst estimates of $100.32 million. Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The business’s revenue for the quarter was up 16.9% on a year-over-year basis. As a group, research analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in TWST. Quarry LP purchased a new stake in Twist Bioscience during the third quarter valued at about $28,000. Smartleaf Asset Management LLC lifted its holdings in shares of Twist Bioscience by 70.6% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after acquiring an additional 442 shares during the last quarter. SBI Securities Co. Ltd. grew its holdings in shares of Twist Bioscience by 68.9% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock valued at $44,000 after purchasing an additional 571 shares during the last quarter. National Bank of Canada FI purchased a new stake in Twist Bioscience during the third quarter valued at about $46,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Twist Bioscience by 15.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock worth $85,000 after buying an additional 302 shares during the period.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on TWST. Evercore ISI upped their target price on Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday, December 29th. TD Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a report on Thursday, January 8th. Robert W. Baird set a $50.00 price target on shares of Twist Bioscience in a research report on Tuesday. Finally, Stephens assumed coverage on Twist Bioscience in a research note on Monday, November 3rd. They issued an “overweight” rating and a $41.00 price objective for the company. Seven research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, Twist Bioscience has an average rating of “Moderate Buy” and an average target price of $45.88.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.